natgillin/translations-raw huggingface dataset:
By comprises a transgene cassette comprising a transgene and a splice acceptor sequence; and is a bond or comprises: E4; wherein the transgene cassette is under the control of an endogenous major late promoter and wherein the transgene cassette comprises a therapeutic gene encoding material selected from the group consisting of an RNAi sequence, a protein, an antibody or binding fragment thereof, a chemokines, a cytokines, an immunomodulator and an enzymes. 
By sadrži transgenu kasetu koja sadrži transgen i slijed akceptora nadovezivanja; i B3 je veza ili sadrži: E4, gdje je transgena kaseta pod kontrolom endogenog promotora koji se bira iz skupine koju čine E4 i glavni kasni promotor, te gdje transgena kaseta sadrži terapijski gen koji kodira materijal koji se bira iz skupine koju čine slijed RNAi, protein, protutijelo ili njegov vežući fragment, kemokin, citokin, imunomodulator i enzim.
The method of claims 1-5, wherein the saccharide and/or protein carrier has been derivatised to comprise amino or carboxyl groups. 
Postupak u skladu s patentnim zahtjevima 1-3, naznačen time što je saharid i/ili proteinski nosač tako deriviran da sadrži amino ili karboksilne skupine.
The discharge device 1 /metered dose valve 2 according to the present invention comprises a dip hose 27 connected to the inlet valve 7 of the metered dose valve 2 and a dip tube 28 within the metering chamber 6 and connected to the outlet valve 8 . 
Naprava za pražnjenje l/ventil za odmjeravanje doze 2 prema predloženom izumu obuhvaća uronjenu cijev 27 povezanu s ulaznim ventilom 7 ventila 2 za odmjeravanje doze i uronjenu cijev 28 unutar odmjerne komore 6 koja je povezana s izlaznim ventilom 8.
The smoking article of the present invention also is capable of providing an aerosol which is chemically simple, consisting essentially of oxides of carbon, air, water, and the aerosol which carries any desired flavorants or other desired volatile materials, and trace amounts of other materials. 
Cigaretni substitut iz sadašnjeg izuma takoder može da osigura aerosol koji je kemijski prost i sastoji se suštinski od oksida ugljika, zraka, vode i aerosola koji nosi makoja željena mirisna sredstva ili druge željena isparljive materijale 1 količine u tragovima drugih materijala.
In another embodiment of the foregoing, the optimized polynucleotide encodes an XTEN sequence with at least about 90% sequence identity to AE48. 
(ili) < aminokiselinsku sekvencu koja ima najmanje 99% identiteta sekvence od aminokiselinske sekvence od AE912-hGH-AE144 koja je prikazana u Tablici 36.
Summary of the Invention An exemplary process for preparing Compound 1: said process comprises the steps of: cyclizing Compound 2 in a first solvent at an elevated temperature wherein R5 and R6 are each independently selected from the group consisting of H, alkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, aryl, alkylaryl, arylalkyl, heterocyclic and heteroaryl groups, or R5 and R6, together with the nitrogen to which they are attached, form a 3- to 6-membered heterocyclic compound containing 1-4 heteroatoms, to produce a first mixture of exo isomers said isomers having a trans-[5,6]-ring-junction and endo isomers: 
(a) ciklizacije Spoja 2 u prvom otapalu, na povišenoj temperaturi gdje svakog od Rs i Rs se neovisno bira iz skupine koju čine H, alkilne, alkenilne, alkinilne, alkoksi, cikloalkilne, arilne, alkilarilne, arilalkilne, heterocikličke i heteroarilne skupine, ili Rs i R4, zajedno s dušikom na kojeg su vezani, tvore 3- do 6-eročlani heterociklički spoj s 1-4 heteroatoma, kako bi se dobilo prvu smjesu exo-izomera gdje navedeni izomeri imaju zrans-[5,6]-vezu u prstenu; i endo-izomera:
The mixture is then processed into granules or processed into tablets. 
Smjesa se tada prerađuje u granule ili preša u tablete.
BRIEF DESCRIPTION OF THE DRAWINGS Figures 1 and 2 are longitudinal views of two embodiments of the invention. The embodiment of the invention illustrated in Fig. 1, which preferably has the diameter of a conventional cigarette, includes a short, combustible carbonaceous fuel element 10, and an abutting aerosol generating means 30. 
Realizacija izuma ilustrirana na Sl. 1, koja poželjno ima promjer konvencionalne cigarete, uključuje kratak, izgorivi ugljični gorivi element 10, dodirno sredstvo 12 za generiranje aerosola, i papirnu cjev 14 obloženu folijom, koja formira dio 15 usnog kraja proizvoda.
MMVF according to numbered embodiment 16 or 17, wherein the MMVF have a composition comprising the following oxides, expressed by wt of oxides: 
Postupak sukladno patentnom zahtjevu 1, naznačen time, što rastaljena tvar sadrži slijedeći sastav, izražen prema masi oksida:
X is an anion selected from the group consisting of chloride or dibenzoyltartrate 
X je anion odabran iz skupine koju čine klorid ili dibenzoiltartrat; jjelili2.
Biological sources such as cell culture supernatants of cells expressing a protein product in a recombinant way may contain less impurities, in particular if the cells are grown in serum-free medium. 
Biološki izvori poput supernatanta iz staničnih kultura koje eksprimiraju rekombinantni proteinski produkt također mogu sadržavati manje nečistoće posebice ukoliko stanice rastu u podlozi koja ne sadrži serum.
Housing 11 includes formed therein an elongate through-going window 59 via which the location of the adjuster nut 26 relative to shank 52, and hence the degree of pre-load applied to the compression spring 24, is visible. 
Kućište 11 sadrži i izduženi prolazni prozor 59, koji je izveden u njemu, pomoću kojega su vidljivi položaj navrtke 26 za podešavanje u odnosu na osovina 52, pa time 1 stupanj predopterećenja koji je primjenjen na kompresijsku oprugu 24.
directing the feedstock stream to a first reaction zone where it is contacted with a metal carbonyl compound and where at least a portion of the ethylene oxide is converted to a carbonylation product stream comprising beta propiolactone; 
usmjeravanja struje sirovine u prvo područje reakcije gdje dolazi u kontakt s metalnim karbonilnim spojem i gdje se u najmanju ruku dio etilen-oksida prevede u struju produkta karboniliranja koja sadrži B-propiolakton;
preparing compound 3 according to the process defined as claim 7; 
pripreme spoja 3 prema postupku definiranom prema barem jednom od zahtjeva 7 do 9;
The method of claim 11, wherein said conjugate is adsorbed onto aluminium phosphate or unadsorbed onto adjuvant, and wherein adsorption takes place either before or after mixing with other antigens. 
Postupak u skladu s patentnim zahtjevom 11, naznačen time što je navedeni konjugat adsorbiran na aluminijev fosfat ili neadsorbiran na adjuvans, te što se adsorciju provodi bilo prije ili nakon miješanja s drugim antigenima.
The compound or a salt thereof according to claim 1, wherein said compound is 2-fluoro-3-[2-(morpholin-4-yl)pyrimidin-5-yl]benzyl carbamimidoylcarbamate, or a salt thereof. 
Spoj ili njegova sol prema zahtjevu 1, naznačen/a time, da navedeni spoj je 2-fluoro-3-[2-(morfolin-4-iDpirimidin-5-il]benzil-karbamimidoilkarbamat, ili njegova sol.
ii) converting the compound of formula (1) into a further compound of formula (1) iii) forming a salt iv) forming a prodrug 
1i) konverziju spoja sa formulom (1) u drugi spoj sa formulom (1) ili) tvorbu soli iv) stvaranje predlijeka
A sensor assembly according to any of claims 1 through 12, wherein said first elongate recess has a depth such that when said first optical fiber, without first longitudinal-strain-inducing jacket coating present, is fully engaged with said first elongate recess, an uppermost portion of said first optical fiber is substantially flush with said first confronting face of said first rigid transverse-load-applying structure. 
Senzoričko sklopovlje u skladu s bilo kojim od patentnih zahtjeva 1 do 12, naznačeno time što navedeni prvi izduljeni žlijeb ima takvu dubinu da kada navedeno prvo optičko vlakno, bez prisutnosti prve obloge koja uzrokuje uzdužno naprezanje, u potpunosti leži u navedenom prvom izduljenom žlijebu, gdje je najgornji dio navedenog prvog optičkog vlakna uglavnom poravnan s navedenom prvom sučeljenom površinom navedene prve čvrsto strukture koja primijenjuje poprečno opterećenje.
and pharmaceutically acceptable salts thereof. A pharmaceutical composition, which comprises a compound of Formula I as defined in claim 33 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable diluent or carrier. 
Farmaceutski sastav, koji sadrži tvar formule I kako je definirana u bilo kojem od patentnih zahtjeva 1 do 23 ili njena farmaceutski prihvatljiva sol i farmaceutski prihvatljivi diluent ili nosač.
An antibody or an antigen-binding fragment thereof according to any one of claims 1 to 9 which recognizes a polypeptide consisting of or comprising the epitope with the sequence of SEQ ID No55 and optionally is raised against said polypeptide. 
Antitijelo ili njegov antigen-vezujući fragment u skladu s bilo kojim od patentnih zahtjeva 1 do 9 koje/koji prepoznaje polipeptid koji se sastoji od ili koji sadrži epitop sa sekvencom u skladu sa SEQ ID No55 i izborno je gajeno protiv navedenog polipeptida.
The present invention relates to a synergistic herbicidal mixture consisting of 
Ovaj izum se odnosi na sinergističku herbicidnu smjesu koja sadrži
The first bearing surface 13 of the socket 20 is perpendicular to the second bearing surface 14 of the socket 20 . 
Futrola prema bilo kojem patentnom zahtjevu od 1 do 3, naznačena time da je prva nosiva površina (13) utora (20) okomita na drugu nosivu površinu (14) utora (20).
Purify the crude product by silica gel chromatography by eluting with 1:1 ethyl acetate/hexane to yield 9.0 g (91 %) of a white solid. 
Sirovi produkt pročisti se kromatografijom na silikagelu, uz eluiranje smjesom 1:1 etil-acetat/heksan kako bi se dobilo 9,0 g (91 %) bijele krutine.
The same reference numerals will generally be used for the same parts as those in Figures 1-6b, even though small differences may occur. 
Isti odnosni brojevi će se općenito koristiti za iste dijelove kao i na slikama 1- 6b, čak ako bi to moglo uzrokovati male razlike.
Resistor 86 shunts conductor 12 at a node downstream transformer 30, in such a way that the current flowing in said resistor 86 returns to the network 10 through conductor 44 and 14 but without flowing through the toroidal core of transformer 30. 
Otpornik 86 premoštava vodič 12 na izlaznom priključku transformatora 30, tako da se struja koja protječe tim otpornikom vraća u mrežu 10 preko vodiča 44 i 14, ali bez da teče kroz toroidnu jezgru transformatora 30.
The present invention relates to a process for the isolation of a phospholipid from a fish oil. 
Postupak za proizvodnju fosfolipidnih proizvoda 1z ribljeg ulja obuhvaća sljedeće korake:
The compound for use according to claim 8, wherein R5 is substituted or unsubstituted heteroaryl; optionally wherein R5 is heteroaryl selected from the group consisting of substituted or unsubstituted pyridyl, substituted or unsubstituted pyridazinyl, substituted or unsubstituted pyrimidinyl, substituted or unsubstituted thienyl, and substituted or unsubstituted furyl. 
Spoj za uporabu prema zahtjevu 8, naznačen time što je R5 supstituirani ili nesupstituirani heteroaril; proizvoljno pri čemu je R5 heteroaril odabran iz skupine koju čine supstituirani ili nesupstituirani piridil, supstituirani ili nesupstituirani piridazinil, supstituirani ili nesupstituirani pirimidinil, supstituirani ili nesupstituirani tienil, i supstituirani ili nesupstituirani furil.
It has been surprisingly found that by means of multiple successive filtrations operated by filters of equal or decreasing aperture within the filtration stations 15a, 15b and 15c, such a device and method enable the size of the crosslinked PMMA present in the material undergoing treatment to be reduced to dimensions considered acceptable and advantageously less than 200 micron diameter. 
Bilo je s iznenađenjem nađeno da pomoću višestrukih filtriranja, koja slijede jedno iza drugog, s filtrima koji imaju jednake otvore ili im se otvori smanjuju, unutar stanica za filtriranje 15a, 15b 1 15c, takav uređaj 1 takav postupak omogućavaju smanjenje veličine umreženog PMMA koji se nalazi u materijalu koji je podvrgnut tretmanu da se smanje dimenzije za koje se smatra da su prihvatljive, a poželjno je da su manje od 200 mikrona u promjeru.
A trap device for controlling an invertebrate pest, comprising: the bait composition of Claim 11 and a housing adapted to receive said bait composition, wherein the housing has at least one opening sized to permit the invertebrate pest to pass through the opening so the invertebrate pest can gain access to said bail composition from a location outside the housing, and wherein the housing is further adapted to be placed in or near a locus of potential or known activity for the invertebrate pest. 
Metoda iz patentnog zahtjeva 8, koja koristi klopku za kontrolu štetnika beskralježnjaka, klopka obuhvaća smjesu u obliku mamca i kućište prilagođeno prihvaćanju navedenog mamca, pri čemu kućište ima barem jedan otvor veličine koja dozvoljava štetnicima beskralježnjacima prolaz kroz otvor tako da štetnici beskralježnjaci mogu pristupiti navedenom mamcu iz smjera izvan kućišta, i gdje je kućište nadalje prilagođeno za smještaj u blizini lokaliteta moguće ili poznate aktivnosti štetnika beskralježnjaka.
Garment, according to claim 1, characterised in that the chain stitch seam consists in the interconnection of the thread (4) in groups forming interlinked loops (4a). 
Odjevni predmet, u skladu s patentnim zahtjevom 1, naznačen time, da se šav sa lančanim ubodom sastoji od povezivanja konca (4) u skupinama koje tvore međusobno povezane petlje (4a).
A pack as claimed in claim 1, wherein said reversible closing means are chosen from the group comprising: a strip of Velcro, a double-sided adhesive, a slider zipper, a zipper with minizip, a zipper with handle, a minigrip closing system. 
Pakiranje prema zahtjevu 1, pri čemu je povratni sklop za zatvaranje izabran iz skupine koju čine: velkro (čičak) traka, dvostrano ljepilo, klizni patent zatvarač, patent zatvarač sa minizatvaračem, patent zatvarač sa drškom, »Mminigrip" sistem za zatvaranje.
The device according to any of claims 16 or 17, wherein at least one of the detaching means carries out a rotational detaching movement. 
Uređaj u skladu s bilo kojim od patentnih zahtjeva 13 ili 14, kod kojega najmanje jedno od sredstava za odvajanje izvodi rotacijsko kretanje kod odvajanja.
A compound of Formula 4 for use in the treatment of an eye disease associated with inflammation and / or vascular proliferation in a subject; wherein the eye disease is selected from the group comprising diabetic retinopathy, corneal edema, anterior and posterior uveitis, pterygium, corneal diseases, dry eye, conjunctivitis, allergy- and laser-induced exudation, non-age related macular degeneration, macular edema, age-related macular degeneration and ocular von Hippel-Lindau disease; 
Spoj formule 4 za uporabu u liječenju bolesti oka povezane s upalom i/ili vaskularnom proliferacijom u subjektu; naznačen time što je bolest oka odabrana iz skupine koja sadrži dijabetsku retinopatiju, edem rožnice, prednji i stražnji uveitis, pterigij, bolesti rožnice, suho oko, konjunktivitis, izlučivanje uzrokovano alergijom i laserom, makularnu degeneraciju nepovezanu s dobi, makularni edem, makularnu degeneraciju povezanu s dobi i očnu von Hippel-Lindau bolest;
data processing system (S3) for processing the data obtained by the electromechanical switch (S1) and by the pressure sensor (S2). 
sustav (S3) za obradu podataka određuje vrijednost brzine toka koja se odnosi na aktivnu kombinaciju kruga ($1.3.1) koji sačinjavaju električni krug (S1.3).
wherein R1 is as defined for the compound of formula (IIa), with a chiral amine of formula (Va) 
(la) pri čemu su R1, R2 1 R6 kao što su definirani u zahtjevu 3; 1 kiralni amin formule (V) ima formulu (Va):
to 99 wt % of a refractory, ceramic and/or construction raw material, wherein said raw material has an average grain size of from 60µm to 50mm; and/or 
,1 do 99 wt % refraktorne, keramičke i/ili konstrukcijske sirovine, pri čemu spomenuta sirovina ima prosječnu veličinu zrna od 60 µm do 50 mm; i/ili
The compound for use of claim 1, wherein the disease or disorder is lymphoma. 
Spoj ili sastav za uporabu prema zahtjevu 3, naznačen time, da bolest ili poremećaj je rak pluća.
The microaggregates (e.g. 
Mikroagregati (na pr.
In another aspect of the present invention an alternative synthetic process for the preparation of compounds of formula (II), or generally of formula (XIII), is provided. 
(iii) prevođenja spoja formule (1), ili njegove soli, u drugi spoj formule (I), ili njegovu sol.
the organoid comprises a single layered epithelial domain where polarized cells are detected and keratin markers are expressed and a second domain, constituting the main body of the organoid, formed by a multilayered epithelia with non-polarized cells, optionally expressing albumin, and/or the organoid is obtained from an epithelial stem cell from an adult liver expressing Lgr5, and which comprises a population of between at least 1x103 cells and 5x104. 
(a) organoid obuhvaća jednoslojno epitelno područje gdje se detektiraju polarizirane stanice 1 markeri keratina su izraženi i drugo područje, koje čini glavno tijelo organoida, obrazovano višeslojnim epitelijem sa ne-polariziranim stanicama, koje opcionalno eksprimiraju albumin, i/ili (b) organoid je dobiven 1z epitelijalne matične stanice iz odrasle jetre koja eksprimira Lgr5, i koja sadrži populaciju između najmanje 1x10* stanica i 5x10".
Cleavage of Pg may be performed under standard conditions for such reactions. 
(ii) cijepanje skupine Pg može se provesti pod standardnim uvjetima za takve reakcije.
an inflammatory disease wherein said disease is an inflammatory disease of the respiratory tract; 
Spoj ili sol prema zahtjevu 74 naznačen time da navedena upalna bolest je upalna bolest dišnih putova.
is pivotally mounted on a corresponding hinge at a level closer to the distal end than to the proximal end of the corresponding latch, said corresponding hinge being located on the hinge frame, such that the the corresponding latch can pivot from a fixing position, wherein the coupling device is fixed to the ladle gate frame, to an idle position, wherein the coupling device is not fixed to the ladle gate frame, 
zakretno postavljen na zglob (36) na razini bližoj distalnom kraju od proksimalnog kraja zasuna, navedeni zasun nalazi se na zglobnom okviru (34h), tako da se zasun može zakretati od položaja pričvršćivanja do položaja praznog hoda, spojen je s elastičnim sredstvima (35) koja su u osnovi nagnuta na način da vode navedeni zasun do fiksiranog položaja,
loaded material, unbound fraction, the acidic wash fraction (50 mM acetate pH 4.5), the WFI wash fraction and the peak eluted with 35% PG, were analysed in SDS-PAGE (Example 5). 
naneseni materijal, nevezane frakcije, frakcije dobivene kiselim ispiranjem (50 mM avetat, pH 4.5), frakcija dobivena ispiranjem s WFI 1 peak eluiran sa 35% PG su analizirani tehnikom SDS-PAGE (Primjer 5).
The rats were allowed to acclimatize to their conditions for at least five days before commencement of the study. 
Å takori su ostavljeni aklimatizirati se njihovim uvjetima barem pet dana prije početka preoučavanja.
a monoclonal antibody that binds to an epitope comprising residues 82-87 of the human CD40 sequence shown in SEQ ID NO:10 or SEQ ID NO:12; a monoclonal antibody that binds to an epitope comprising residues 82-89 of the human CD40 sequence shown in SEQ ID NO:10 or SEQ ID NO:12; 
€) monoklonalnog antitijela koje se veže za epitop koji sadrži ostatke 82-89 humane CD40 sekvence prikazane u SEQ ID br.:10 ili SEQ ID br:12; 1 d) monoklonalnog antitijela koje kompetira s monoklonalnim antitijelom CHIR-5.9 koje se dobiva iz hibridomske stanične linije koja je pohranjena kod tvrike ATCC kao patentna pohrana br.
a compound of the glycylcycline class, especially tigecycline, or pharmaceutically acceptable salts, or hydrates or solvates thereof. 
Orn je ($)-2,5-diaminopentanska kiselina; i tigeciklin, ili njegove farmaceutski prihvatljive soli, ili hidrati ili solvati.
said waste water is fed for fluidized-bed thermophilic aerobic biological treatment, inside a closed reactor (1), provided with a thermostat control system (2) and with a hydraulic recirculation system (3); 
- < ta otpadna voda se dovodi za termofilnu aerobnu biološku obradu u fluidiziranom sloju, unutar zatvorenog reaktora (1), u kojem postoji termostatski kontrolni sustav (2) 1 hidraulički recirkulacijski sustav (3);
A composition for use according to Claim 1, wherein the cyclodextrin is 2-hydroxypropyl-B-cyclodextrin and is present at a concentration of 25%, and the buffer is 10 mM phosphate at pH 7.4. 
Pripravak namijenjen upotrebi u skladu s patentnim zahtjevom 1, naznačen time što je ciklodekstrin 2- hidroksipropil-B-ciklodekstrin i prisutan je u koncentraciji od 25%, a puferje 10 mM fosfat s pH 7,4.
dewatering and dispersing the precipitated calcium carbonate seeds prepared in step (a) to obtain an aqueous suspension of precipitated calcium carbonate seeds having a d 50 of less than or equal to 0.1 to 0.3 µm and a BET specific surface area of 10 to 30 m2/g, and 
(b) uklanjanje vode i dispergiranje sjemena taložnog kalcijevog karbonata pripremljenog u koraku (a) da se dobije vodena suspenzija sjemena taložnog kalcijevog karbonata koje ima dsg od manje od ili jednako 0.1 do 0.3 um i specifičnu površinu prema BET-u od 10 do 30 m/g, i
cooling the biscuits obtained; and packaging said biscuits; wherein the step c) of baking said semi-finished products comprises a step of exposure thereof to a hot gas consisting of hot air and superheated steam, blown directly on said semi-finished products by means of an impingement system. 
€) pakiranje dobivenih keksa; pri čemu korak c) pečenja polugotovih proizvoda obuhvaća korak izlaganja proizvoda vrućem plinu koji se sastoji od vrućeg zraka 1 zagrijane pare, koji se ispuhuje izravno na polugotovi proizvod pomoću padajućeg sustava.
The method of any one of claims 1-7, wherein each subject in the population has a BMI of ≥30. 
Metoda zahtjeva 1 do 7, pri čemu uzorak sadrži serum, krv ili plazmu.
A pharmaceutical composition comprising a therapeutically effective amount of a compound of claim 1, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier. 
Farmaceutski pripravak koji sadrži terapijski učinkovitu količinu spoja prema bilo kojem od zahtjeva 1 do 12, ili njegove farmaceutski prikladne soli, i farmaceutski prikladan nosač.
System for the application of stabilized non smoking TCE according to the claim 11 wherein the system includes a mechanism for temperature control (16) with a thermostat which it registers at any time the temperature inside the tunnel (1) and that it is programmed by a temperature of control below which the mechanism of control interrupts automatically the supply of electricity to the dosing pump (7), interrupting the pulverization of mixture of stabilized non smoking TCE and air to the interior of the tunnel (1). 
Sistem za prekrivanje staklenih površina sa kompozicijom baziranom na bezvodnom kositar tetrakloridu prema patentnom zahtjevu 8 pri čemu sistem uključuje mehanizam (16) za kontrolu temperature sa termostatom koji registrira u bilo koje vrijeme temperaturu unutar tunela (1) i koji je programiran pomoću temperature kontrole ispod koje mehanizam kontrole automatski prekida opskrbu električnom energijom pumpe (7) za doziranje, prekidajući raspršivanje smjese kompozicije bazirane na bezvodnom kositar tetrakloridu i zraka u unutrašnjosti tunela (1).
The use of a post-combustion system as complementary heating component of the kiln described at point 3) with an operating temperature range of 1100-1300 °C, necessary for the thermal treatment of all the volatile compounds and eventually the asbestos fibres released during the preliminary stage of the firing process described at point 3). 
Proces prema zahtjevu 1, naznačen time da spomenuta kontinuirana tunelska peć uključuje jedan sustav post-sagorijevanja čija se radna temperatura kreće od 1100-1300 °C, za termičku obradu hlapljivih spojeva i azbestnih vlakana koja nastaju tijekom spomenutog ciklusa pečenja